Navigation Links
Omeros Announces it has Unlocked 30 Percent of Class A Orphan GPCRs
Date:1/10/2012

chizophrenia, bipolar disease and depression) as well as all other antihistamines, opioids, alpha and beta blockers, serotonergics and dopaminergics. 

The industry focuses its GPCR drug discovery efforts mostly on non-sensory GPCRs. Of the 363 total non-sensory GPCRs, approximately 240 have known ligands (molecules that bind the receptors) with nearly half of those targeted either by marketed drugs (46 GPCRs) or by drugs in development (about 70 GPCRs). There are approximately 120 GPCRs with no known ligands, which are termed "orphan GPCRs." Without a known ligand, drug development for a given receptor is extremely difficult.

Omeros uses its proprietary high-throughput CRA to identify small-molecule agonists and antagonists for orphan GPCRs, unlocking them to drug development. Omeros believes that it is the first to possess the capability to unlock orphan GPCRs in high-throughput, and that currently there is no other comparable technology. Unlocking these receptors could lead to the development of drugs that act at these new targets. There is a broad range of indications linked to orphan GPCRs including cardiovascular disease, asthma, diabetes, pain, obesity, Alzheimer's disease, Parkinson's disease, multiple sclerosis, schizophrenia, learning and cognitive disorders, autism, osteoporosis, osteoarthritis and several forms of cancer.

About Omeros Corporation

Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system. The Company's most clinically advanced product candidates are derived from its proprietary PharmacoSurgery™ platform designed to improve clinical outcomes of patients undergoing a wide range of surgical and medical procedures. Omeros has four ongoing clinical development programs. Omeros may also have the near-term capability, through its GPCR program, to add a l
'/>"/>

SOURCE Omeros Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Omeros Announces It Has Unlocked Over 20 Percent of Class A Orphan GPCRs
2. Omeros to Present at Rodman and Renshaw 13th Annual Healthcare Conference
3. Omeros to Present at Two Upcoming Conferences
4. Omeros to Present at Future Leaders in the Biotech Industry Conference
5. Omeros to Present at Needham Healthcare Conference
6. Omeros Corporation Awarded $1.7 Million in Grants Under the Qualifying Therapeutic Discovery Project Program
7. Omeros Announces Additional Support from the National Institute on Drug Abuse for Clinical Studies in Addiction Program
8. Omeros Secures $40 Million Committed Equity Financing Facility
9. Omeros To Webcast Presentation at Ninth Annual Needham Healthcare Conference
10. Omeros to Webcast Presentation at Deutsche Bank 35th Annual Health Care Conference
11. Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... Genedata, a leading provider of advanced ... research, today announced that Pfizer Inc. has licensed ... at Pfizer biopharma research and development sites in ... global deployment and roll out project at Pfizer’s ... (CTI), and Pharmaceutical Sciences groups. , “Pfizer ...
(Date:3/3/2015)... 2015 Research and Markets ( ... PharmaBiotech,s new report "Personalized Medicine - Scientific ... , The aim of personalized medicine ... drug to the right patient and, in some ... a patient according to his/her genotype. This report ...
(Date:3/3/2015)... , Mar. 03, 2015 Research and ... the addition of Jain PharmaBiotech,s new report ... to their offering. , Gene ... vectors, nonviral vectors and cell therapy with genetically ... of drug delivery and various routes of administration ...
(Date:3/3/2015)... 2015 Elsevier,s DirectCourse online ... competency-based training to comply with new CMS requirements ... a new crosswalk tool to help providers ... for direct service workers as a means to comply ... regulations. CMS amended the regulations, effective March ...
Breaking Biology Technology:Genedata Biologics Licensed by Pfizer Inc. 2Genedata Biologics Licensed by Pfizer Inc. 3Global Personalized Medicine Market Report 2015 - Scientific and Commercial Aspects 2014-2024 2Global Personalized Medicine Market Report 2015 - Scientific and Commercial Aspects 2014-2024 3Gene Therapy Market Report 2014-2024 - Technologies, Markets and Companies 2Gene Therapy Market Report 2014-2024 - Technologies, Markets and Companies 3Elsevier's DirectCourse Can Help States Meet and Exceed New CMS Requirements for Home and Community-Based Services 2Elsevier's DirectCourse Can Help States Meet and Exceed New CMS Requirements for Home and Community-Based Services 3
... to fuel requires several steps: chemical pretreatment to break ... to remove the toxic chemicals required in pretreatment, and ... Virginia Tech researchers have discovered an enzyme mixture that ... biomass (hydrolysate), meaning that the detoxification step is unnecessary, ...
... 2011 Cadence Pharmaceuticals, Inc. (Nasdaq: ... commercializing proprietary product candidates principally for use in the hospital ... and full year ended December 31, 2010 financial results on ... host a conference call and live webcast to discuss the ...
... Bulletin Board: GOVX ), an Atlanta-based biotechnology company ... its financial results for the fourth quarter and year ended ... of $478,784 for the fourth quarter ended December 31, 2010, ... comparable period in 2009. For the full year of 2010, ...
Cached Biology Technology:Enzyme cocktail could eliminate a step in biofuel process 2GeoVax Labs Reports Fourth Quarter and Year-End 2010 Financial Results 2GeoVax Labs Reports Fourth Quarter and Year-End 2010 Financial Results 3GeoVax Labs Reports Fourth Quarter and Year-End 2010 Financial Results 4GeoVax Labs Reports Fourth Quarter and Year-End 2010 Financial Results 5GeoVax Labs Reports Fourth Quarter and Year-End 2010 Financial Results 6
(Date:2/5/2015)... 5, 2015  Marken is starting its 35 th ... launched a new marketing campaign to solidify its place ... new campaign focuses on First as a ... The first headline in the series, ... with its client,s priorities. Marken recognizes the need to ...
(Date:2/5/2015)... 27, 2015   Marvin Test Solutions ... innovative test solutions for military, aerospace, and ... its TS-323 GENASYS Test Platform ... GENASYS is a high-performance PXI-based system designed ... that require performance functional testing. GENASYS features ...
(Date:2/5/2015)... DUBLIN , Jan. 28, 2015 Research ... announced the addition of the "Global Biometrics ... Use, Regions and Countries " report to their ... market, Asia-Pacific is anticipated ... by 2015, owing to increasing government spending towards ...
Breaking Biology News(10 mins):Marken Launches New Patient-Centric Campaign 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 2Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 3
... led by a New York University School of Medicine scientist ... Hudson River to live in waters heavily polluted by PCBs. ... issue of Science , they report that a population ... the toxic chemicals, which were first introduced in 1929, and ...
... algae do the dirty work. Researchers at Rochester ... in wastewater. The project is doubly "green" because algae ... in the water. The end result: clean wastewater and ... can be channeled back into receiving bodies of water ...
... The research could eventually lead to new approaches for ... livestock which are caused by trypanosomes carried by the ... sexual reproduction evolved very early and is now ubiquitous ... all living organisms except bacteria). However, real evidence ...
Cached Biology News:A genetic mutation allows Hudson River fish to adapt to PCBs 2The green machine: Algae clean wastewater, convert to biodiesel 2Shining a light on trypanosome reproduction 2
Rat Antibody to Mouse TCR VB8.1,8.2:FITC Recognises the V beta 8.1 and V beta 8.2 determinants of the murine T cell receptor. Specificity: mouse TCR VB8.1 and 8.2...
fli-1...
Vesicle Associated Membrane Protein (VAMP 1/2)...
Anti-Mouse Valpha 2 TCR, Purified (Clone B20.1) (rat IgG2a)...
Biology Products: